Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Arterial Hypertension
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Reviewers 2023

Vol 3, No 2 (1999)
Commentary
Published online: 2000-03-08
Get Citation

United Kingdom Prospective Diabetes Study /UKPDS) - Clinical Aspects

Peter T. Sawicki
Nadciśnienie tętnicze 1999;3(2):108-111.
Vol 3, No 2 (1999)
Komentarz
Published online: 2000-03-08

Abstract

Intensive blood-glucose control by either sulphonyloareas or insulin substantially decreases the risk of microvascular complications, but not macrovacsular disease, in patients with type 2 diabetes. None of the individual drugs had an adverse effect on cardiovascular outcomes. All intensive treatment increased the risk of hypoglycaemia. Metformin may be the first line pharmacological therapy of choice in overweight diabetic patients, since intensive glucose control with ofmetformin appears to decrease the risk of diabetes-related endpoints in overweight diabetic patients, and is associated with less weight gain and fewer hypoglycaemic attacks than are insulin and sulphonylureas. Tight blood pressure control in patients with hypertension and type 2 diabetes achieves a clinically important reduction in the risk of deaths related to diabetes, complications related to diabetes and progression of diabetic retinopathy. Blood pressure lowering with captopril or atenolol was similary effective in reducing the incidence of diabetic complications. The study provided no evidence that either drug has any specific beneficial effect, suggesting that blood pressure reduction in itself may be more important than the treatment used.

Abstract

Intensive blood-glucose control by either sulphonyloareas or insulin substantially decreases the risk of microvascular complications, but not macrovacsular disease, in patients with type 2 diabetes. None of the individual drugs had an adverse effect on cardiovascular outcomes. All intensive treatment increased the risk of hypoglycaemia. Metformin may be the first line pharmacological therapy of choice in overweight diabetic patients, since intensive glucose control with ofmetformin appears to decrease the risk of diabetes-related endpoints in overweight diabetic patients, and is associated with less weight gain and fewer hypoglycaemic attacks than are insulin and sulphonylureas. Tight blood pressure control in patients with hypertension and type 2 diabetes achieves a clinically important reduction in the risk of deaths related to diabetes, complications related to diabetes and progression of diabetic retinopathy. Blood pressure lowering with captopril or atenolol was similary effective in reducing the incidence of diabetic complications. The study provided no evidence that either drug has any specific beneficial effect, suggesting that blood pressure reduction in itself may be more important than the treatment used.
Get Citation

Keywords

diabetes mellitus type 2; hypertension; microvascularcomplications; macrovascular complications; β-blockers; ACE-inhibitors; sulphonylureas; metformin; insulin

About this article
Title

United Kingdom Prospective Diabetes Study /UKPDS) - Clinical Aspects

Journal

Arterial Hypertension

Issue

Vol 3, No 2 (1999)

Article type

Commentary

Pages

108-111

Published online

2000-03-08

Page views

824

Bibliographic record

Nadciśnienie tętnicze 1999;3(2):108-111.

Keywords

diabetes mellitus type 2
hypertension
microvascularcomplications
macrovascular complications
β-blockers
ACE-inhibitors
sulphonylureas
metformin
insulin

Authors

Peter T. Sawicki

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl